ARG tyrosine kinase activity is inhibited by STI571

Blood

Volumn 97, Issue 8, 2001, Pages 2440-2448

  Okuda, K ^a   Weisberg, E ^a   Gilliland, D G ^a   Griffin, J D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLT3 LIGAND; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL TRANSFORMATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE FUSION; LEUKEMIA REMISSION; MOUSE; MYELOID LEUKEMIA; NEURULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REMISSION;

EID: 0035871874     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.8.2440     Document Type: Article

References (40)

1. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
2. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
3. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
4. Clinical efficacy and safety of an Abl-specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
5. A novel human gene closely related to the abl proto-oncogene
6. The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases
7. Arg encodes a widely expressed 145-kDa protein-tyrosine kinase
8. Essential roles for the Abl and Arg tyrosine kinases in neurulation
9. A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12) (q25;p13) translocation
10. The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): Molecular cloning of both reciprocal transcripts
11. Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms
12. Fusion of platelet-derived growth factor beta to a novel ets-like gene in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
13. Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines
14. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway
15. p210BCP/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines
16. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes
17. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways
18. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
19. Expression of high amounts of the CD117 molecule in a case of B-cell non-Hodgkin's lymphoma carrying the t(14:18) translocation
20. Translocation t(8;13)(p11;q11-12)in stem cell leukemia/lymphoma of T-cell and myeloid lineages
21. Localization of the 8;13 translocation breakpoint associated with myeloproliferative disease to a 1.5 Mbp region of chromosome 13
22. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia
23. Protein tyrosine kinase inhibitors as novel therapeutic agents
24. Clinical strategy for the development of angiogenesis inhibitors
25. Reversibility of acute B-cell leukaemia induced by BCR-ABL1
26. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
27. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
28. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
29. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP57148
30. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
31. Tyrosine phosphorylation of RNA polymerase II carboxyl-terminal domain by the Abl-related gene product
32. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways
33. Subcellular localization of the Arg protein tyrosine kinase
34. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
35. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia
36. The novel activation of ABL by fusion to an ets-related gene, TEL
37. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25)
38. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins
39. The second ETV6 allele is not necessarily deleted in acute leukemias with a ETV6/ABL fusion
40. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion